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ABBREVIATIONS 
AAG  Autoimmune autonomic ganglionopathy  
AIDs Autoimmune disorders 
AIDP                                      Acute inflammatory demyelinating polyradiculoneuropathy  
AIH Autoimmune hepatitis 
AIT Autoimmune toxicity 
ATG                                       Anti-thymocyte antiglobulin 
AZA                                      Azathioprine 
CIDP                                     Chronic inflammatory demyelinating polyradiculoneuritis 
CNI                                       Calcineurin inhibitor 
CP                                         Cyclophosphamide 
CTLA-4                                Cytotoxic T lymphocyte-associated antigen 4  
GBS                                      Guillain-Barré syndrome  
ICIs             Immune-checkpoint inhibitors 
IBD             Inflammatory bowel disease 
irAE(s)                                  Immune-related adverse event(s) 
IS                                           Immunosuppression 
IVIGs                                    Intravenous immunoglobulins 
mAbs                                     Monoclonal antibodies 
MG                                        Myasthenia gravis 
MMF                                     Mycophenolate mofetil 
PD-1              Programmed death 1 receptor 
PD-L1             Programmed death-ligand 1 
SLE                                       Systemic lupus erythematosus 
SJS                                        Stevens-Johnson syndrome 
TAMs                                    Tumor-associated macrophages 
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ABSTRACT 
 
Immune-checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancer types and 
are progressively becoming a standard of care for many of them. Cancer immunotherapy has 
started a revolution in the oncology therapeutic landscape, bringing new hope to patients but 
also a whole new spectrum of toxicities for practitioners to manage. Oncologists and 
specialists involved in the pluridisciplinary management of immune-related adverse events 
(irAEs) are increasingly confronted with the therapeutic challenge of severe and/or refractory 
cases. In this personal view, we summarize the therapeutic strategies reported to manage 
them. Based on current knowledge of irAE pathogenesis and our immunological expertise, 
we also transpose the use of new biologic and non-biologic immunosuppressive agents, used 
to treat primary autoimmune disorders (AIDs), in the context of severe and/or steroid 
refractory irAE management. Depending on the immune-type predominant infiltrate, we 
propose a personalized treatment algorithm beyond corticosteroids. A shut-off strategy, 
intended to treat severe or steroid-refractory irAEs, based on the efficient inhibition of key 
inflammatory components involved in their pathophysiological processes, and limit potential 
adverse effects of drug immunosuppression on tumor response is proposed. This approach 
goes beyond current guidelines, challenging the step-by-step increase in drug 
immunosuppression proposed so far. 
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INTRODUCTION 
 
Monoclonal antibodies that block immune checkpoints, such as the cytotoxic T-lymphocyte 
antigen 4 (CTLA-4)-CD28 and programmed death 1 (PD-1)-programmed death ligand 1 (PD-
L1) axes, are the main immunotherapies prescribed in the current oncological practice. Over 
the last decade, clinicians have been confronted with the management of irAEs resulting from 
ICI therapies. Because of the increasingly widespread use of ICIs in oncology, new data on 
toxicities related to these agents are continuously reported, in addition to the ones 
documented in prospective clinical trials. The advent of double checkpoint inhibition 
constitutes also a new challenge as the related toxicities often involve multiple organs and 
occur at higher frequencies compared to monotherapy. For example, the prospective 
Checkmate 067 trial on ipilimumab/nivolumab combination in advanced melanoma reported 
a 4% incidence of patients with steroid-refractory irAEs.1 The spectrum of organ systems 
affected by irAEs is very broad and their management often requires expertise that goes 
beyond the specialty of oncology. They vary in frequency and severity, depending on the 
agent(s) and the affected system(s). Consequently, their optimal management requires 
experienced multidisciplinary teams. Extensive knowledge in the field of clinical 
immunology and immunosuppressive therapy, going beyond current guidelines, is often 
required of such teams. Another crucial challenge is the need for early recognition and 
prompt treatment of irAEs to avoid adverse outcomes due to delayed patient care. Like most 
treatment-related toxicities in oncology, irAEs should be managed according to grade. 
Nevertheless, one should not overlook the limitations of current grading systems, and thus 
should not to substitute them for clinical judgment, especially in frail patients and when 
confronted with rapidly evolving irAEs. In this personal view, we discuss personalized 
therapeutic options for severe and/or refractory irAEs, based on current immuno-
pathophysiological knowledge and on extrapolations from primary autoimmune counterparts.  
 
High-quality guidelines regarding the management of irAEs were released by the European 
Society of Medical Oncology (ESMO)2, the National Comprehensive Cancer Network 
(NCCN) and the Society for Immunotherapy of Cancer (SITC) Toxicity Management 
Working Group.3,4 They provide treatment algorithms for most frequent irAEs in a 
comprehensive way and detail their recommendation regarding the use of 
immunosuppressive drugs according to irAE severity and duration. They also emphasize the 
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importance of avoiding delays in the work-up to rule-out other differential diagnoses (e.g., 
infectious complications or tumor progression) before initiating effective immunosuppressive 
therapy. However, as exhaustive as these guidelines can be, they are still limited regarding 
the management of severe and/or refractory irAEs, with which clinicians are confronted in 
the day-to-day practice. Retrospective data on a large ipilimumab-treated cohort reported that 
more than one-third of patients received corticosteroids to manage an irAE, and one-third of 
those required additional immunosuppressive drugs.5 It is important to be aware that rare yet 
life-threatening irAEs are constantly reported, representing a diagnostic and therapeutic 
challenge; for such irAEs, evidence to guide management recommendations is limited due to 
the scarcity of literature, consisting of only small series or case reports. Some experts are 
already adopting a first instance cytokine-directed therapy, such as tocilizumab (an IgG1 
humanized anti-IL6R mAb), in steroid-refractory cases.6  
 
 
NEW THERAPEUTIC PERSPECTIVES TO MANAGE ICI-INDUCED TOXICITIES 
 
Due to the scarcity of prospective trials regarding drug immunosuppression in the setting of 
high-grade irAEs, in daily clinical practice one draws from small series, case reports and 
expert opinion to handle challenging cases. Current guidelines promote a step-by-step 
approach, starting with high-dose steroids and increasing drug immunosuppression as 
needed. This consensus will certainly be maintained in the absence of validated clinical or 
biological biomarkers predictive of steroid-refractoriness. On the other hand, clinicians 
confronted with severe irAEs should not discard the possibility to add a cytokine-directed 
mAb from the beginning of a severe irAE with the putative advantage of “shutting-off” early 
a rapidly evolving immuno-pathophysiological process, thereby avoiding patient exposure to 
extended courses of immunosuppression. A good example for first instance aggressive drug 
immunosuppression is myocardial irAEs. In this case, better efficacy of rapid 
immunosuppression is presumed due to its fulminant clinical presentation, the high 
associated morbi-mortality rate, as well as the documented increased risk of adverse 
outcomes with lower steroid doses compared to high-dose therapy.7 A recent meta-analysis 
revealed an incidence of fatalities surrounding 1% in ICI treated patients.8 These severe 
irAEs tended to occur early after treatment initiation with monotherapy (with a median of 
forty days) and even earlier with ICI combination (with a median of two weeks). Unusual 
clinical presentations along with diagnosis delays surged as mortality contributing factors.  
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Biomarker-based approaches are already being explored and will certainly help therapeutic 
decision. For example, in ICI-related colitis, ulcerative endoscopic finding have recently been 
suggested as predictive surrogate markers for steroid-refractoriness.9 A recent study on 90 
colic biopsies from patients with ICI-related colitis showed different profiles of immune 
infiltrates:  27% of patients had immune infiltrates with predominant intraepithelial 
lymphocytosis, whereas 73% of patients had predominant monocytic/neutrophilic infiltrates.9  
 
Not to mention that transposing therapeutic knowledge from primary autoimmune disorders 
is also hampered by the different nature of irAEs in terms of disease phenotype, response to 
treatment and pathophysiological mechanisms. For example, a histologic analysis conducted 
on liver biopsies showed a more diffuse, cytotoxic T-cell predominant, and lobular infiltrate 
pattern in comparison to autoimmune hepatitis (AIH), altogether with less CD4 T-cells and 
plasma cells in the parenchyma.10 The lack of steroid efficacy in AIH in comparison to most 
ICI related hepatitis signs also a clear-cut difference highlighting the possible implication of 
CD4 T-cells in steroid refractoriness.11 Multidrug-refractory cases of severe hepatitis have 
been treated with anti-thymocyte antiglobulin (ATG), reflecting the relative resistance to 
selective immunosuppression of this particular irAE.12,13 Another contrasting example is the 
one of ICI-related myasthenia gravis (MG) where a higher risk of crisis compared to their 
autoimmune counterparts, as well as an increased association with myositis has been 
reported.14,15,16 In the opposite, ICI-related colitis displays some interesting common features 
with inflammatory bowel disease (IBD). Both of these disorders demonstrate sensitivity to 
anti-TNFα mAbs and share as well histological and pathophysiological features. The latter is 
highlighted  by the link between IBD and certain CTLA4 polymorphisms in the population.17 
Even though the chronic nature of IBD tends to disrupt the epithelial layer and show 
granulomatous lesions as characteristic features, a lymphocytic-neutrophilic infiltrate is a 
shared histologic feature.  
In light of the present lack of validated biomarkers, immunopathological patterns could be 
considered as rational target tools to personalize a shut-off strategy (Figure 2): For a 
predominant T-cell infiltrate, a T-cell-directed therapy such as anti-IL-6, anti-IL-1R or anti-
IL-12/23 blockade strategy could be an optimal approach. A prominent B/plasma cells 
infiltrate might be optimally targeted by an anti-B-cell strategy (anti-CD20 and/or anti-BAFF 
blockade). An infiltrate with a predominant neutrophilic/monocytic pattern with or without 
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granulomas could be optimally targeted by an anti-TNFα strategy. Lastly, the difficulty to 
obtain a biopsy across clinical contexts and depending on the organs involved, as in the case 
of neurological, rheumatological and ocular irAEs is recognized. The use of a cytokine-
directed mAb, targeting IL-6, TNFα and/or IL-1 pathway is still an upfront option to consider 
in these cases, as it will be discussed later on. 
 
For the most part, the safety profile of biologic and non-biologic agents used in primary AIDs 
extrapolated to cancer patients is still incompletely clear. Some of these drugs are considered 
to have a low likelihood of adverse impact on cancer response, while others may adversely 
affect T-cell antitumor response and consequently cancer prognosis. Altogether, their use 
outside of clinical trials should be advised and monitored by specialists in clinical 
immunology and discussed in light of cancer prognosis, anticipated time of onset of the 
chosen drugs, and their respective side effect profiles.  
 
Knowledge extrapolated from solid organ transplant patients treated with ICIs supports a 
significant impact of calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) on the 
T-cell response. Even so, the latter is already advised as second line immunosuppressive 
drugs in current guidelines. However, in our opinion, they should be avoided in immunogenic 
tumors, especially if a curative intent is at stake, such as in advanced melanoma patients. 
Knowing the role of IL-6 as a major acute inflammatory phase mediator, in cytotoxic T-cells 
differentiation, but also its protumor properties, an IL-6 targeting strategy constitutes a robust 
substitute to older immunosuppressive drugs, without compromising the efficacy of 
immunotherapy.18,19 
  
Limitations of such strategies regarding their cost and financial impact on health care systems 
should be acknowledged. Nevertheless, if the strategy is effective, such costs might be 
amortized thanks to decreased morbidity. In any case, they should be considered in light of 
the already high costs ensuing from ICI therapies. Prospective clinical trials answering these 
open questions are urgently advocated, due to the rapid expansion of cancer immunotherapy. 
Nevertheless, most of these toxicities are so rare that clinical trials are almost inconceivable. 
This is why it is essential to actively report irAEs to competent national authorities and to 
publish them in the medical literature, along with empirically treated cases and case series. 
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The following section provides an overview of standard and off-label agents used to treat 
severe/refractory irAEs as an adjunct to corticosteroids. In principle, we propose to continue 
each such therapy until the complete resolution of the respective irAE (Table 1). 
 
Corticosteroids 
 
By virtue of to their rapid action and convenient use, corticosteroids are still considered the 
first-line treatment of severe irAEs. Commonly used regimens comprise oral prednisone (1 to 
2 mg/kg) or parenteral methylprednisolone (bolus range of 125 to 1000 mg). High-dose 
corticosteroids carry an inherent risk of infectious complications and metabolic disturbances 
(iatrogenic Cushing’s syndrome), and therefore weaning should be started at early signs of 
recovery. However, a tapering period of four to six weeks is advocated to avoid flare 
phenomena relative to the long half-life of ICI mAbs.4 
 
Calcineurin inhibitors (CNI), azathioprine (AZA), mycophenolate mofetil (MMF) and anti-
TNFα therapies  
 
Treatments used for IBD and AIH have been used by extrapolation to treat colitis and 
hepatitis resulting from checkpoint blockade. Severe and refractory irAE colitis can be 
treated with infliximab (a chimeric monoclonal anti-TNFα antibody) at a single dose of 5 
mg/kg, by analogy with Crohn’s disease20. This treatment has been shown to be highly 
effective for corticosteroid-refractory colitis, with rapid responses occurring in 1 to 3 days. In 
some relapsing cases, a second dose is necessary after 2 weeks. Maintenance treatment 
should be reserved for chronic and relapsing cases. Infliximab is also advocated in steroid-
refractory pneumonitis, although with very heterogenous successes reported in the 
literature.21 Nevertheless, anti-TNFα therapy seems a better alternative than older IS drugs in 
this indication. As one of the most frequent irAEs during anti-PD-1/PD-L1 therapies, steroid-
refractory pneumonitis lacks tremendously of evidence-based therapeutic approaches. This 
frail population is also frequently subjected to unfortunate long courses of steroids as 
pneumonitis often demonstrates steroid-dependency. Etanercept, adalimumab, certolizumab 
and golimumab are also available and could be alternatives to infliximab given their excellent 
safety profiles and proven effectiveness. A published case of corticosteroid- and 
methotrexate-refractory ICI-induced polyarthritis treated with adalimumab revealed excellent 
symptomatic improvement together with clinical regression of joint inflammation.22 
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Infliximab is also a rescue option in the treatment of refractory AIH, suggesting that this is 
another reasonable indication for the other anti-TNFα agents.23 A special caution in using 
anti-TNFα mAbs to treat irAEs is also advocated by the rare cases of paradoxical adverse 
events reported under these treatments. In the literature, these encompass mostly the 
emergence or aggravation of psoriasis, IBD, lung granulomatous disease and uveitis, but the 
full spectrum of rarer paradoxical AEs is even wider.24,25 Consequently, clinicians should 
always consider paradoxical AEs in their differential diagnosis in front of refractory irAEs, 
especially if these tend to change of tissue/organ involvement and phenotype during 
treatment with biological agents.  
Possible protocols could be adalimumab 40 mg every two weeks, golimumab 50 mg once per 
month, etanercept 50 mg once per week or certolizumab 400 mg once per month. 
MMF is considered a second-line treatment for ICI-induced hepatitis and is also advocated by 
most current guidelines as a second-line therapy based on a relatively low level of evidence; 
by analogy with AIH, azathioprine could also be a reasonable treatment option.20 CNI have 
been used as adjunct treatment for corticosteroid-refractory colitis and hepatitis, although 
evidence supporting their use in this setting is not well documented.26 A case of infliximab-
refractory enterocolitis has also demonstrated a rapid improvement after two weeks of 
cyclosporine. Perhaps a focus on its ability to potentially prevent myocardial fibrosis should 
also be brought to the attention of clinicians and be addressed in surviving cohorts of ICI-
induced myocarditis.27 Plasma dosing and levels-based scheduling of MMF and CNI 
administration should be performed in order to confirm the therapeutic doses and avoid 
toxicity. 
 
Beyond the aforementioned tested immunosuppressive/immunomodulatory drugs to treat 
severe/refractory irAE cases, additional options can be envisaged by extrapolating knowledge 
from the treatment of primary AIDs (Figure 1).  
 
Anti-IL-1 blockade 
 
IL-1 is one of the main cytokines present during the acute phase of inflammation. Preclinical 
data have identified the IL-1beta pathway as an important promoter of tumor progression 
through stimulation of tumor-associated macrophages (TAMs), myeloid suppressive cells and 
up-regulation of PD-L1 in tumor cells.28 In addition, CNS injury leads to an inflammatory 
response that is partly mediated by an increase in IL-1 levels through tissue infiltration by 
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neutrophils.26 As shown in several animal models, IL-1 receptor antagonists possess CNS-
protective properties.29 Preclinical studies pointed out the central role of IL-1 in autoimmune 
encephalitis, through its effect on the differentiation of IL-17 producing T-cells.30 It is also a 
mediator of T-cell adhesion to brain microvasculature in certain blood-brain barrier 
preclinical models.31.Anakinra, a recombinant IL-1 receptor antagonist, and canakinumab, a 
monoclonal antibody with anti-IL-1beta activity, are approved for the treatment of 
rheumatoid arthritis and other auto-inflammatory diseases, respectively. IL-1 blockade is 
accepted as having no detrimental effect on cancer response.32 An anti-IL-1 strategy 
employing anakinra or canakinumab may find a place as primary therapy for some irAEs, 
such as acute phase MG, encephalitis, aseptic meningitis, severe arthritis, chronic 
inflammatory demyelinating polyradiculoneuritis (CIDP), psoriasis, auto-inflammatory 
diseases, or severe anti-TNFα-refractory colitis, pneumonitis and myocarditis. A possible 
protocol could be anakinra 100 mg once/day or canakinumab 300-600 mg every 8 weeks. 
   
Anti-IL-6 blockade 
 
Together with IL-1 and TNFα, one of main cytokines in the acute inflammation phase is IL-
6. Additionally, IL-6 has been reported to promote cancer development and metastasis, and to 
function as a main cytokine in the generation of a systemic inflammatory response and the 
expansion of cancer-related symptoms, leading to the deterioration in physical performance 
and quality of life.33 Furthermore, anti-IL-6 therapy appears to be very effective for severe 
IBD that does not respond to traditional therapy targeting TNFα.34 
Consequently, the use of anti-IL-6 therapy as an upfront treatment could be an excellent 
alternative to anti-TNFα or anti-IL-1 agents for many irAE indications, without 
compromising the efficacy of immunotherapy. Serum IL-6 has proven to be a useful marker 
of rheumatoid arthritis disease activity.35 However, elevated serum levels of IL-6 are frequent 
in cancer patients.36 Nevertheless, a baseline IL-6 level assessment before ICI therapy 
followed by repeated measurements in case of irAE emergence could still be a useful 
biomarker. A serious caution is advocated in interpreting these results, as they can also sign 
tumor progression or an infectious complication. The elevation of serum IL-6 should not be 
considered a decisive factor in the introduction of anti-IL-6 therapy, as it has not been 
validated in dedicated clinical trials. A prospective trial planning to assess the efficacy of 
first-line tocilizumab treatment in ICI-induced colitis and arthritis is about to initiate 
(NCT03601611). Amongst other measurements, the levels of IL-6 and CRP will be taken in 
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an attempt to validate theses serum markers as irAE activity biomarkers and evaluate their 
usefulness in therapeutic decisions. A retrospective trial showed a statistically significant 
correlation between C-reactive protein levels (an indirect surrogate of IL-1, IL-6 and TNFα 
serum levels) and irAE emergence as response to tocilizumab therapy in a cohort mainly 
represented by lung cancer patients and clinical improvement was observed in 79.4% of 
patients, with 52.9% of the patients requiring only a single dose for symptomatic response.6 
Possible indications for anti-IL-6 therapy include severe irAEs in their acute phase, severe 
arthritis, uveitis, Graves’ orbitopathy, myocarditis, large-vessel vasculitis, severe pneumonitis 
and MG.37-42 A possible protocol might comprise 8-mg/kg tocilizumab-administered i.v. once 
per month or 162 mg administered subcutaneously once per week. However, its use should 
be used carefully in cases of refractory ICI-induced enterocolitis due to a potential increased 
risk of lower gastrointestinal track perforation, as reported in rheumatoid arthritis 
patients.43,44 
 
 
Anti-IL-17 therapy 
 
High IL-17 serum levels have been reported during ipilimumab-induced colitis.45 Blockade 
through monoclonal antibodies such as secukinumab may constitute an interesting strategy to 
manage this toxicity. However, contradictory evidence regarding IL-17 and its implications 
in promoting tumor growth and metastasis has raised concern.46 For example, a patient with 
metastatic colon cancer (with a mismatch repair-deficient tumor) who initially responded to 
PD-1 blockade, showed tumor progression after treatment with secukinumab for a psoriatic 
rash.47 In view of the heterogeneous microenvironment across tumor types and individuals, 
the identification of profiles that might be able to predict the role of IL-17 in tumor control 
or, conversely, tumor promotion should be pursued. Possible indications for use of anti-IL-17 
therapy are severe psoriasis refractory to anti-TNFα therapy and rheumatoid arthritis. Several 
mAbs are available and could be used as follows: ixekizumab 80 mg s.c. every two weeks, 
brodalumab 210 mg s.c. every two weeks and secukinumab 150 mg s.c. every week.  
 
Anti-IL-23/12 therapy 
 
Ustekinumab is a mAb targeting the common p40 subunit of IL-23 and IL-12. It is approved 
for the treatment of cutaneous psoriasis and related arthritis. A randomized trial comparing 
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ustekinumab to placebo in the setting of anti-TNFα-refractory Crohn’s disease showed that 
one-third of patients experienced a response at 6 weeks.48 Opposing roles of IL-23 and IL-12 
in maintaining outgrowth and dormancy of tumors in mice raise concerns regarding the use 
of ustekinumab in cancer patients. Nevertheless, most clinical trials did not find an 
unexpected increase in cancer rates across approved indications.49,50 In the palliative and 
refractory irAE setting, ustekinumab treatment may be a conceivable option in selected cases. 
A possible protocol is: induction dose of 6 mg/kg i.v. followed by 90 mg every 8 to 12 
weeks. 
 
Anti-integrin 4 
 
Natalizumab is an anti-integrin 4 antibody that is approved for the treatment of multiple 
sclerosis. It has also been used in a relapsing case of limbic encephalitis in a patient with 
stage IV SCLC, leading to cognitive improvement without impairing a durable tumor 
response with a combined checkpoint inhibition.51 Vedolizumab is an anti-integrin α4β7 
antibody showing in gut-selective anti-inflammatory activity, with indication for the 
treatment of refractory IBD.52 Its efficacy has been reported in a case-series of seven steroid-
refractory cases of ICI-induced colitis, obtaining a remission in six patients. Two to four 
vedolizumab administrations seemed enough to obtain steroid-free remission in their cohort, 
with no adverse side-effect of vedolizumab reported.53    
   
 
Janus kinase inhibition 
 
Tofacitinib, a Jak 1/3 inhibitor, is currently used across several rheumatological indications, 
such as refractory rheumatoid arthritis and ulcerative colitis.54 On the other hand, some 
reports suggest that the risk of lower GI tract perforation associated with tofacitinib treatment 
among rheumatoid arthritis patients may be more common than with other anti-TNFα agents, 
suggesting the need for close clinical follow-up during the treatment of ICI-induced colitis.43 
A possible dosing scheme could be 5 mg or 10 mg twice per day. 
 
Anti-B-cell strategy 
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As the major role of T cells is well established in the pathogenesis of irAEs, yet several 
studies have also reported a possible contributive role of B-cells, especially in skin irAEs 
(with bullous phenotype) and endocrine irAEs (e.g. in hypophysitis and thyroiditis).55-57 
Recently, a first report described peripheral blood changes in B-cell number and qualitative 
sub-populations in melanoma patients treated with ICIs.58 Using flow cytometry, Das et al. 
revealed a correlation between irAEs occurrence and severity to the reduction of B-cell 
compartment with concomitant increase in CD21low B-cells and plasmablasts. Although the 
pathophysiological mechanisms linking these changes to irAE triggering or promotion are 
still lacking, their potential as predictive biomarkers of irAE occurrence is already raising 
interest. The absence of measurable auto-antibodies is not an argument discarding the role of 
B-cells in the pathogenesis of irAEs, since they are also absent in 60% of patients with 
primary Sjögren’s syndrome associated to small-fiber polyneuropathy.59 Such seronegative 
cases require more specific diagnostic approaches including neuromuscular or salivary glands 
biopsy. Rituximab treatment has also demonstrated to be effective in seronegative AIDs, as 
for example cutaneous vasculitis and ANCA-negative vasculitis.60,61,62  
    
Autoimmune encephalitis is a rare but dreadful irAE that is often associated with double 
checkpoint blockade, as reported in different tumor types. Cases have been reported in which 
anti-neural autoantibodies were detected, such as anti-NMDAR63 or anti-Hu64; in other cases, 
such antibodies were undetectable. In several reports, both type of cases (i.e. independently 
of serologic status), showed an impressive neurologic improvement after treatment with 
rituximab (anti-CD20 monoclonal antibody); in these cases, patients were mostly 
unresponsive to corticosteroids and IVIGs.63,65 Thus, whether autoantibodies are directly 
pathogenic (i.e., anti-NMDAR), directed against intra-cytoplasmic antigens (i.e., anti-Hu), or 
undetectable, rituximab can be considered as a therapeutic alternative, with probably low 
impact on tumor control. Additionally, rituximab could be an excellent option for ICI-
induced AIDs with an autoantibody profile, such as SLE, severe SJS, ANCA-associated 
vasculitis, cutaneous vasculitis, autoimmune autonomic ganglionopathy (AAG), sensory 
ganglionopathy, nephritis, MG, transverse myelitis, enteric neuropathy and encephalitis. 
Furthermore, rituximab can also be used to treat autoimmune hepatitis or refractory 
hemolytic anemia in patients intolerant or refractory to standard regimens.66 Interestingly, 
tumor-associated B-cells in melanoma have been implicated in drug resistance and to detain a 
pro-tumorigenic property in part through IGF-1 secretion.67 CD20 is also aberrantly 
expressed in subsets of melanoma cells with stem cell properties and is being studied as a 
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target antigen for chimeric antigen receptor T-cell therapy (CART).68 A pilot study including 
ten patients with therapy-resistant melanoma showed an activity of B-cell depletion with 
ofatumumab in eight of them, thus suggesting at least a good safety profile regarding this 
kind of immunosuppression on tumor control. Encouraging data from case-series have also 
been published showing median survival exceeding one year in multi-treated metastatic 
melanoma patients receiving rituximab.69 Possible protocols are two courses of rituximab 1 g 
two weeks apart or 375 mg/m2 once per week for 4 weeks. Other fully human anti-CD20 
antibodies are also available: ofatumumab 300 mg on day 1 and 1000 mg on day 2, 
obinutuzumab 1000 mg on days 1 and 2, and ocrelizumab 300 mg on days 1 and 4. Because 
these new human anti-CD20 antibodies seem to have an excellent safety profile and at least 
similar effectiveness as rituximab, they may provide a possible alternative to rituximab. 
Belimumab (anti-BAFF mAb) has proven its efficacy in SLE and may be an option as an 
adjunct to rituximab in severe/refractory autoantibody-mediated irAEs, as this combination 
may induce a more profound B-cell depletion by acting on plasma cells activation.70 Thereby, 
it remains important to define the best combination B-cells therapy as well as the appropriate 
sequence. 
A possible deleterious effect on tumor control should lead to a careful assessment of patient’s 
risk and potential benefits.    
 
Intravenous immunoglobulins (IVIGs) and plasmapheresis  
 
IVIGs are the standard treatment for Guillain-Barré syndrome (GBS) as well as subacute and 
CIDP. Dramatic improvements in ICI-induced cases of GBS or CIPD have been reported 
using standard approaches with protocols of 400 mg/kg/day for 5 days.71 Immune 
thrombocytopenia is a rare irAE whose occurrence may cause delays in the instauration of 
further anticancer treatment and place the patient at life-threatening risk for bleeding, 
especially in populations with a high prevalence of CNS metastasis, such as melanoma 
patients. Three-quarters of patients will respond to corticosteroids; refractory cases may 
require CNI treatment or IVIGs.72 Thrombopoietin agonists such as romiplostim have also 
been used in the setting of anti-PD-1-induced thrombocytopenia.73 Use of IVIGs should be 
limited in view of their intense, albeit short-lasting, effect. Possible indications for IVIGs are 
GBS, subacute and chronic inflammatory neuropathies, immune thrombocytopenia, facial 
nerve palsy, MG, transverse myelitis, enteric neuropathy, ocular myositis and encephalitis.74 
A case of severe corticosteroid-refractory autoimmune neutropenia responding to IVIG 
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following ipilimumab treatment has also been reported.75 A possible protocol might be 400 
mg/kg/day for 5 days once per month for a total of 3 to 4 treatments. 
A case of MG crisis showed a favorable outcome for at least 6 months after 
methylprednisolone, IVIGs and 5 courses of plasmapheresis.15 As the treatment backbone of 
GBS relies on the latter, corticosteroid-refractory immune-related AIDP and/or encephalitis 
patients could be considered as potential candidates for plasmapharesis.76 
 
 
Cyclophosphamide (CP)  
 
Despite its carcinogenic risk, a pulse of CP may be very useful as an induction treatment for 
remission in multiple severe irAEs, such as symptomatic sarcoidosis, steroid-refractory 
pneumonitis, GBS, severe SJS with central and neurological symptoms, AAG, sensory 
ganglionopathy, polyneuropathy and central neuritis. An induction protocol is CP (10 to 15 
mg/kg) at weeks 0, 2, 4, 7, 10 and 13 (cumulative dose of ~7 g) or 500 mg every two weeks 
for a total of 6 cures, similar to its use for SLE nephritis. 
 
Cyclophosphamide-rituximab 
 
In order to achieve rapid remission with minimal exposure to the carcinogenic risk of CP, an 
appropriate alternative protocol to 6 CP cures could comprise 4 administrations of rituximab 
(375 mg/m2) at weeks 0, 1, 2 and 3 and two administrations of CP (10 to 15 mg/kg) at weeks 
0 and 2.77 
 
 
CONCLUSION 
 
The development of cancer immunotherapy is one of the major medical breakthroughs. We 
are only at the beginning of a new era and we are still learning how to make the best use of 
these novel potent therapies in the management of cancer patients. We have however been 
facing the appearance of severe toxicity associated with immunotherapy, often with 
substantial challenges in the management of severe irAEs. Because their clinical course and 
response to therapy may differ from the ones observed in primary AIDs, we are still learning 
how to adapt and optimize classic immunosuppressive interventions for the treatment of 
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irAEs. This learning process will take time and will require advances in three areas: (i) the 
development of biomarkers predictive of steroid-refractoriness, early response to 
immunosuppressive therapy and safety of ICIs administration; (ii) the development of 
appropriate therapeutic regimens using classic immunosuppression, i.e. corticosteroids, 
together with efficient mAb/small molecule therapies blocking inflammation; and (iii) the 
training of a new generation of physicians with specific expertise in immunotherapy.   
 
Because the clinical presentation of irAEs and their severity vary from patient to patient, in 
part due to intrinsic factors, the identification of genetic, epigenetic or surrogate predictive 
markers of irAEs development is expected to allow a better safety appraisal of ICI therapies 
in patients at high risk of irAEs (as well as for those with preexisting AIDs) and to guide the 
development of preventive interventions. High-throughput RNA sequencing of peripheral 
mononuclear blood cells or circulating micro-RNAs could be explored to identify predictive 
signatures of irAE development and be used as non-invasive biomarkers. As a proof of 
principle, this area of research has already shown promising results in stem cell transplant 
recipients at risk of graft-versus host disease.78,79 Biomarkers are also needed to develop 
personalized treatment algorithms by choosing the most appropriate shut-off strategy to 
manage severe and refractory irAEs, e.g., according to the immune type of the predominant 
infiltrate from the affected organ(s), as determined by biopsy. A crucial incentive from the 
medical community should also be given to include prospective investigations on side effect 
management in future advanced phase trials.  
Such approaches could inform the direct and selective targeting of main inflammatory 
cytokines, such as IL-6, TNFα and/or IL-1, together with ICIs discontinuation, without 
compromising the efficacy of immunotherapy. The expected benefit of this upfront shut-off 
strategy is two-fold: blockade of the acute phase of the inflammatory reaction, and inhibition 
of tumor development promoted by IL-1 and IL-6.  
 
Finally, a new generation of clinicians with specific training and expertise in immunotherapy 
is needed, due to the evolving complexity of cancer care and the large spectrum of immune-
related toxicities. Furthermore, the proper management of severe irAEs requires the efficient 
response and concerted decision and of multidisciplinary teams, thus, this type of training 
crosses the traditional boundaries of medical specialties. Such efforts will ensure that cancer 
patients benefit from the highest quality care during the ongoing immunotherapy revolution.  
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Table 1. New therapeutic perspectives for the management of irAEs 
 
Figure 1. Immunosuppressive drug summary according to respective targets. In 
response to the acute inflammatory phase, many cytokines are continuously secreted, notably 
IL-1, IL-6 and TNFα. By analogy with IBD treatment, blocking TNFα by infliximab has been 
proposed to treat irAE colitis. New humanized anti-TNFα antibodies, such as adalimumab 
and golimumab, could be alternatives to infliximab, likely exhibiting similar efficiency with 
fewer allergic side effects. IL-1 and IL-6 are also acute phase targets; blocking these 
cytokines would impair their stimulatory effect on helper T-cells, B-cells, NK cells, 
macrophages, plasma cells and hematopoietic stem cells, as well as their endothelial 
activation properties. This could be more efficient than classically advocated anti-TNFα 
strategies. Using a shut-off interruption strategy by applying an anti-IL6 (tocilizumab) or 
anti-IL1 (anakinra, canakinumab) agent may have additional advantages because of the pro-
tumor and pro-metastatic activities of IL-6 and IL-1. Anti-IL-1 therapy could also be a useful 
adjunctive treatment in cases of ICI-induced encephalitis in which the inflammatory response 
is mainly driven by IL-1 increase. B-cell depletion (with rituximab, obinutuzumab, 
ofatumumab or belimumab) could be helpful for neurological or hematological complications 
of ICIs, as well as in ICI-induced connective tissue diseases, severe SJS and vasculitis-related 
irAEs. In addition, IL-12/23 targeting could suppress the acute inflammation phase by 
impairing the positive stimulatory effect of IL-23 on TNFα secretion, which could thus be 
indicated in irAE cases refractory to anti-TNFα agents. Anti-IL-17 strategy could be used to 
treat cutaneous irAEs, such as anti-TNFα-refractory psoriasis-like reactions. 
 
Figure 2. Personalized shut-off treatment algorithms for refractory irAEs according to 
immune-type predominant infiltrate. For a predominant T-cell infiltrate, a T-cell-directed 
therapy such as anti-IL-6 blockade could be considered, whereas for a prominent B/plasma 
cell infiltrate component, an anti-B-cell strategy (anti-CD20 and/or anti-BAFF blockade) 
could be considered. Regarding an infiltrate with predominant neutrophilic and monocytic 
features with or without granulomatous features, an anti-TNFα strategy would be a plausible 
option. In case of a clinical and/or biological improvement, another administration could be 
performed two weeks later if the initial response is not considered sufficient. Also, in case of 
response, steroid tapering should be initiated and pursued over a 4-6-week period. If a tissue 
biopsy is not available, an anti-IL-6, anti-IL-1 or anti-TNFα strategy are reasonable options. 
As second-line treatment, an anti-IL1, anti-IL-12/23 or anti-IL-17 agent may be considered 
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after a first line with an anti-IL-6 therapy; if not available, then an anti-TNFα strategy may be 
an option. If no improvement is observed after the second administration repeated after two 
weeks, a third line should be considered. For that, we propose an anti-integrin 4 agent 
(Natalizumab) as a first choice; if not available, then a non-selective IS or a Janus Kinase 
inhibitor could also be considered. If no improvement is observed after the second 
administration repeated after two weeks, a fourth line could be considered, such as 
cyclophosphamide 10-15 mg/kg and/or plasmapheresis. The fourth line could be repeated 
more than twice until irAE resolution. The administration of IVIG could be considered for 
GBS and CDIP at any moment. 
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New therapeutic options 
irAE indications Protocols 
Anti-IL-1 blockade 
Severe irAE during acute phase 
Severe or refractory arthritis 
Chronic inflammatory demyelinating 
polyradiculoneuritis (CIDP) 
Psoriasis-like reactions/ 
Psoriasis exacerbation  
Severe and/or anti-TNFα refractory colitis  
Myasthenia gravis  
Encephalitis  
Aseptic meningitis 
Myocarditis 
Pneumonitis 
- Anakinra: 100 mg 1x/d 
- Canakinumab 300-600 mg 1x/ 8 
weeks  
Anti-IL-6 blockade 
Severe irAE during acute phase 
Severe or refractory arthritis 
Large vessel vasculitis  
Uveitis 
Myocarditis 
Pneumonitis 
Myasthenia gravis 
-Tocilizumab at 8 mg/kg, 
intravenously 1x/month or 
subcutaneous 162 mg 1x/week 
 
Intravenous 
immunoglobulins (IVIGs) 
Guillain-Barré syndrome  
Subacute and chronic inflammatory 
demyelinating polyradiculoneuritis (CIDP) 
Subacute and chronic inflammatory 
neuropathies 
Immune neutropenia 
Immune thrombocytopenia 
Facial nerve palsy 
Myasthenia gravis 
Transverse myelitis  
Enteric neuropathy 
Encephalitis  
Aseptic meningitis 
400 mg/kg/day for 5 days, 
1x/month for a total of 3-4 cures.  
  
Anti-CD20 depletion 
  
Systemic lupus erythematosus SLE  
Severe Sjögren's syndrome SjS 
ANCA associated vasculitis 
Cutaneous vasculitis 
Autoimmune autonomic ganglionopathy 
Sensory ganglionopathy 
Nephritis 
Myasthenia gravis 
Transverse myelitis  
Enteric neuropathy 
Encephalitis  
Aseptic meningitis 
Hepatitis 
-Rituximab: 1g every two weeks 
for 2 cures or 375 mg/m2 1x/week 
for 4 cures 
- Ofatumumab 300 mg day 1 and 
1000 mg day 2 
- Obinutuzumab 1000 mg at day 1 
- Ocrelizumab 300 mg at day 1 
and day 4. 
Anti-IL-17 blockade Severe colitis and anti-TNFα refractory 
colitis  
Severe or refractory arthritis 
 
-Ixekizumab 80 mg sc 1x/2 weeks  
-Brodalumab 210 mg sc 1x/2 
weeks  
-Secukinumab 150 mg sc 1x/2 
weeks  
  
Anti-TNFα blockade 
Severe colitis  
Hepatitis 
Severe or refractory arthritis 
Nephritis 
Uveitis  
Pneumonitis 
Myocarditis 
-Infliximab 5 mg/kg 1x/2 weeks 
-Adalimumab 40 mg 1x/ 2 weeks  
-Golimumab 50 mg 1x/month  
-Etanercept 50 mg 1one time by 
week  
-Certolizumab 400 mg one time 
by month.  
  
Anti-integrin 4 blockade Limbic encephalitis -Natalizumab 300 mg 1x/month 
  
Anti-IL-23/12 blockade Acute phase 
Severe or anti-TNFα refractory colitis 
Severe or anti-TNFα refractory psoriasis 
Severe or refractory arthritis 
  
-Ustekinumab 
initial dose 40 mg than 45 mg 
after 4 weeks and then 45 mg 
every 12 weeks 
Janus Kinase inhibitor  
  
Severe or refractory arthritis 
  
-Tofacatinib 5 mg 2x/day 
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